{{Rsnum
|rsid=1059510
|Gene=HLA-E
|Chromosome=6
|position=30489955
|Orientation=minus
|GMAF=0.3085
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=HLA-E
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 10.6 | 49.6 | 39.8
| HCB | 9.5 | 39.4 | 51.1
| JPT | 6.2 | 38.9 | 54.9
| YRI | 5.5 | 30.1 | 64.4
| ASW | 14.0 | 47.4 | 38.6
| CHB | 9.5 | 39.4 | 51.1
| CHD | 11.0 | 45.9 | 43.1
| GIH | 5.0 | 24.8 | 70.3
| LWK | 3.6 | 48.2 | 48.2
| MEX | 13.8 | 36.2 | 50.0
| MKK | 0.6 | 23.7 | 75.6
| TSI | 8.8 | 44.1 | 47.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1059510
|Name_s=HLA-E: mRNA 332C>A/G/T (Asn98Lys/Lys/Asn)
|Gene_s=HLA-E
|Feature=
|Evidence=PubMed ID:16538176
|Annotation=Risk or phenotype-associated allele: T allele (98Asn). Phenotype: Carbamazepine (CBZ)-induced maculopapular exanthema (MPE). Study size: 162. Study population/ethnicity: 18 CBZ-induced MPE cases and 144 CBZ-tolerant controls of Chinese descent. Significance metric(s): p = 0.005176, OR = 2.79. Type of association: GN; PD; TOX; ADR.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=Drug Hypersensitivity; Exanthema; Maculopapular Exanthema
|Curation Level=Curated
|PharmGKB Accession ID=PA165291966
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1059510
|overall_frequency_n=5227
|overall_frequency_d=7512
|overall_frequency=0.69582
|n_genomes=48
|n_genomes_annotated=0
|n_haplomes=79
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23582631
|Title=Pathway analysis of genome-wide association studies on rheumatoid arthritis
}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}